Verona Pharma plc - American Depositary Share (VRNA) Social Stream



Verona Pharma plc - American Depositary Share (VRNA): $3.77

0.02 (+0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 413

in industry

Verona Pharma plc (VRNA) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Verona Pharma plc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 4 $25 $17 $20.6 $4.89 321.27%
2022-01-24 4 $25 $17 $21.6 $4.89 341.72%
2022-03-07 5 $25 $17 $21.6 $4.89 341.72%

The Trend in the Analyst Price Target


VRNA's average price target has moved up $4.35 over the prior 17 months.

VRNA reports an average of 276.14% for its upside potential over the past 117 days.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-10 5 25 17 20.6 5.080 305.51%
2021-11-12 5 25 17 21.6 5.250 311.43%
2022-01-24 5 25 17 21.6 6.125 252.65%
2022-03-04 5 25 17 21.6 5.450 296.33%
2022-03-07 5 25 17 21.6 4.960 335.48%

VRNA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 5 0 0 0 0 5

The Trend in the Broker Recommendations


Over the past 120 days, VRNA's average broker recommendation rating improved by 0.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for VRNA as an investment opportunity.

  • In terms of how Verona Pharma plc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 372.98% of that group.
  • In the context of all US stocks, Verona Pharma plc's number of analysts covering the stock is greater than 94.12% of them.
  • In the context of all US stocks, Verona Pharma plc's average analyst price target is higher than 97.06% of them.
  • In terms of how Verona Pharma plc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -23.44% of that group.

Stocks similar to Verona Pharma plc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are VRCA, VNDA, and VKTX.

What is the outlook for VRNA? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.0397 seconds.